Fortress Biotech (FBIO) Competitors

$2.87 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

FBIO vs. ENTA, PALI, IKT, VNDA, and NMRA

Should you buy Fortress Biotech stock or one of its competitors? Fortress Biotech's main competitors and comparable companies include Enanta Pharmaceuticals (ENTA), Palisade Bio (PALI), Inhibikase Therapeutics (IKT), Vanda Pharmaceuticals (VNDA), and Neumora Therapeutics (NMRA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Fortress Biotech compare to Enanta Pharmaceuticals?

Enanta Pharmaceuticals (NASDAQ:ENTA) and Fortress Biotech (NASDAQ:FBIO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings and risk.

In the previous week, Enanta Pharmaceuticals had 4 more articles in the media than Fortress Biotech. MarketBeat recorded 4 mentions for Enanta Pharmaceuticals and 0 mentions for Fortress Biotech. Enanta Pharmaceuticals' average media sentiment score of 0.21 beat Fortress Biotech's score of 0.00 indicating that Enanta Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Enanta Pharmaceuticals	Neutral
Fortress Biotech	Neutral

Enanta Pharmaceuticals has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market. Comparatively, Fortress Biotech has a beta of 1.21, indicating that its share price is 21% more volatile than the broader market.

Fortress Biotech has a net margin of 163.32% compared to Enanta Pharmaceuticals' net margin of -96.89%. Fortress Biotech's return on equity of 83.47% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enanta Pharmaceuticals	-96.89%	-61.84%	-20.70%
Fortress Biotech	163.32%	83.47%	42.98%

Fortress Biotech has lower revenue, but higher earnings than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enanta Pharmaceuticals	$65.32M	6.00	-$81.89M	-$2.41	N/A
Fortress Biotech	$63.26M	1.51	$6.82M	$2.64	1.09

95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are owned by institutional investors. 11.5% of Enanta Pharmaceuticals shares are owned by insiders. Comparatively, 28.5% of Fortress Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Enanta Pharmaceuticals currently has a consensus price target of $19.50, suggesting a potential upside of 44.77%. Fortress Biotech has a consensus price target of $17.00, suggesting a potential upside of 492.33%. Given Fortress Biotech's higher possible upside, analysts clearly believe Fortress Biotech is more favorable than Enanta Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Fortress Biotech beats Enanta Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Fortress Biotech compare to Palisade Bio?

Palisade Bio (NASDAQ:PALI) and Fortress Biotech (NASDAQ:FBIO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

Palisade Bio has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market. Comparatively, Fortress Biotech has a beta of 1.21, suggesting that its stock price is 21% more volatile than the broader market.

Fortress Biotech has higher revenue and earnings than Palisade Bio. Palisade Bio is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palisade Bio	$250K	1,463.87	-$16.78M	-$0.48	N/A
Fortress Biotech	$63.26M	1.51	$6.82M	$2.64	1.09

11.8% of Palisade Bio shares are held by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are held by institutional investors. 0.1% of Palisade Bio shares are held by company insiders. Comparatively, 28.5% of Fortress Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Palisade Bio had 9 more articles in the media than Fortress Biotech. MarketBeat recorded 9 mentions for Palisade Bio and 0 mentions for Fortress Biotech. Fortress Biotech's average media sentiment score of 0.00 beat Palisade Bio's score of -0.21 indicating that Fortress Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Palisade Bio	Neutral
Fortress Biotech	Neutral

Fortress Biotech has a net margin of 163.32% compared to Palisade Bio's net margin of 0.00%. Fortress Biotech's return on equity of 83.47% beat Palisade Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palisade Bio	N/A	-33.47%	-31.79%
Fortress Biotech	163.32%	83.47%	42.98%

Palisade Bio currently has a consensus price target of $9.00, suggesting a potential upside of 328.57%. Fortress Biotech has a consensus price target of $17.00, suggesting a potential upside of 492.33%. Given Fortress Biotech's higher possible upside, analysts clearly believe Fortress Biotech is more favorable than Palisade Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Fortress Biotech beats Palisade Bio on 11 of the 17 factors compared between the two stocks.

How does Fortress Biotech compare to Inhibikase Therapeutics?

Fortress Biotech (NASDAQ:FBIO) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment.

96.5% of Fortress Biotech shares are owned by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 28.5% of Fortress Biotech shares are owned by insiders. Comparatively, 7.1% of Inhibikase Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Fortress Biotech's average media sentiment score of 0.00 equaled Inhibikase Therapeutics'average media sentiment score.

Company	Overall Sentiment
Fortress Biotech	Neutral
Inhibikase Therapeutics	Neutral

Fortress Biotech presently has a consensus target price of $17.00, indicating a potential upside of 492.33%. Inhibikase Therapeutics has a consensus target price of $5.40, indicating a potential upside of 125.94%. Given Fortress Biotech's higher possible upside, research analysts clearly believe Fortress Biotech is more favorable than Inhibikase Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.00

Fortress Biotech has a net margin of 163.32% compared to Inhibikase Therapeutics' net margin of 0.00%. Fortress Biotech's return on equity of 83.47% beat Inhibikase Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortress Biotech	163.32%	83.47%	42.98%
Inhibikase Therapeutics	N/A	-42.80%	-40.58%

Fortress Biotech has a beta of 1.21, suggesting that its share price is 21% more volatile than the broader market. Comparatively, Inhibikase Therapeutics has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market.

Fortress Biotech has higher revenue and earnings than Inhibikase Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortress Biotech	$63.26M	1.51	$6.82M	$2.64	1.09
Inhibikase Therapeutics	$260K	1,282.69	-$48.26M	-$0.43	N/A

Summary

Fortress Biotech beats Inhibikase Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Fortress Biotech compare to Vanda Pharmaceuticals?

Fortress Biotech (NASDAQ:FBIO) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends.

Fortress Biotech has higher earnings, but lower revenue than Vanda Pharmaceuticals. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortress Biotech	$63.26M	1.51	$6.82M	$2.64	1.09
Vanda Pharmaceuticals	$216.10M	1.48	-$220.47M	-$4.63	N/A

Fortress Biotech currently has a consensus target price of $17.00, indicating a potential upside of 492.33%. Vanda Pharmaceuticals has a consensus target price of $13.70, indicating a potential upside of 159.47%. Given Fortress Biotech's higher possible upside, analysts plainly believe Fortress Biotech is more favorable than Vanda Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Fortress Biotech has a beta of 1.21, suggesting that its share price is 21% more volatile than the broader market. Comparatively, Vanda Pharmaceuticals has a beta of 0.64, suggesting that its share price is 36% less volatile than the broader market.

In the previous week, Vanda Pharmaceuticals had 2 more articles in the media than Fortress Biotech. MarketBeat recorded 2 mentions for Vanda Pharmaceuticals and 0 mentions for Fortress Biotech. Vanda Pharmaceuticals' average media sentiment score of 1.13 beat Fortress Biotech's score of 0.00 indicating that Vanda Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Fortress Biotech	Neutral
Vanda Pharmaceuticals	Positive

96.5% of Fortress Biotech shares are owned by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. 28.5% of Fortress Biotech shares are owned by insiders. Comparatively, 10.7% of Vanda Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Fortress Biotech has a net margin of 163.32% compared to Vanda Pharmaceuticals' net margin of -127.41%. Fortress Biotech's return on equity of 83.47% beat Vanda Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortress Biotech	163.32%	83.47%	42.98%
Vanda Pharmaceuticals	-127.41%	-49.81%	-33.29%

Summary

Fortress Biotech beats Vanda Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Fortress Biotech compare to Neumora Therapeutics?

Neumora Therapeutics (NASDAQ:NMRA) and Fortress Biotech (NASDAQ:FBIO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings.

Neumora Therapeutics presently has a consensus price target of $6.57, indicating a potential upside of 303.16%. Fortress Biotech has a consensus price target of $17.00, indicating a potential upside of 492.33%. Given Fortress Biotech's higher probable upside, analysts clearly believe Fortress Biotech is more favorable than Neumora Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Neumora Therapeutics has a beta of 2.75, indicating that its share price is 175% more volatile than the broader market. Comparatively, Fortress Biotech has a beta of 1.21, indicating that its share price is 21% more volatile than the broader market.

Fortress Biotech has higher revenue and earnings than Neumora Therapeutics. Neumora Therapeutics is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.23	N/A
Fortress Biotech	$63.26M	1.51	$6.82M	$2.64	1.09

47.7% of Neumora Therapeutics shares are owned by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are owned by institutional investors. 26.9% of Neumora Therapeutics shares are owned by insiders. Comparatively, 28.5% of Fortress Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Neumora Therapeutics had 29 more articles in the media than Fortress Biotech. MarketBeat recorded 29 mentions for Neumora Therapeutics and 0 mentions for Fortress Biotech. Neumora Therapeutics' average media sentiment score of 0.21 beat Fortress Biotech's score of 0.00 indicating that Neumora Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Neumora Therapeutics	Neutral
Fortress Biotech	Neutral

Fortress Biotech has a net margin of 163.32% compared to Neumora Therapeutics' net margin of 0.00%. Fortress Biotech's return on equity of 83.47% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neumora Therapeutics	N/A	-242.28%	-131.32%
Fortress Biotech	163.32%	83.47%	42.98%

Summary

Fortress Biotech beats Neumora Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Fortress Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FBIO vs. The Competition

Export

Metric	Fortress Biotech	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$95.71M	$12.49B	$7.32B	$12.82B
Dividend Yield	N/A	2.62%	2.54%	10.78%
P/E Ratio	1.09	789.80	272.90	24.25
Price / Sales	1.51	795.77	632.64	97.63
Price / Cash	N/A	15.47	29.03	36.90
Price / Book	1.44	10.48	11.25	6.42
Net Income	$6.82M	$2.81B	$3.47B	$348.89M
7 Day Performance	1.77%	2.63%	2.33%	0.57%
1 Month Performance	-14.07%	5.22%	7.72%	4.90%
1 Year Performance	26.43%	7.34%	25.22%	17.06%

Fortress Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FBIO Fortress Biotech	1.6523 of 5 stars	$2.87 flat	$17.00 +492.3%	+26.4%	$95.71M	$63.26M	1.09	170	Gap Down
ENTA Enanta Pharmaceuticals	1.6296 of 5 stars	$12.83 -2.5%	$19.50 +52.0%	+52.5%	$383.29M	$65.32M	N/A	160	Analyst Downgrade
PALI Palisade Bio	2.6383 of 5 stars	$2.15 +0.5%	$9.00 +318.6%	+178.5%	$372.94M	$250K	N/A	10
IKT Inhibikase Therapeutics	1.4287 of 5 stars	$2.39 -0.8%	$5.40 +125.9%	N/A	$336.28M	$260K	N/A	6
VNDA Vanda Pharmaceuticals	3.1617 of 5 stars	$5.26 +0.8%	$13.70 +160.5%	+11.2%	$315.61M	$216.10M	N/A	290

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FBIO) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fortress Biotech (FBIO) Competitors

FBIO vs. ENTA, PALI, IKT, VNDA, and NMRA

How does Fortress Biotech compare to Enanta Pharmaceuticals?

Summary

How does Fortress Biotech compare to Palisade Bio?

Summary

How does Fortress Biotech compare to Inhibikase Therapeutics?

Summary

How does Fortress Biotech compare to Vanda Pharmaceuticals?

Summary

How does Fortress Biotech compare to Neumora Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBIO vs. The Competition

Fortress Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Fortress Biotech (FBIO) Competitors

FBIO vs. ENTA, PALI, IKT, VNDA, and NMRA

How does Fortress Biotech compare to Enanta Pharmaceuticals?

Does the media favor ENTA or FBIO?

Which has more risk and volatility, ENTA or FBIO?

Is ENTA or FBIO more profitable?

Which has higher earnings & valuation, ENTA or FBIO?

Do institutionals and insiders hold more shares of ENTA or FBIO?

Do analysts recommend ENTA or FBIO?

Summary

How does Fortress Biotech compare to Palisade Bio?

Which has more volatility & risk, PALI or FBIO?

Which has stronger earnings and valuation, PALI or FBIO?

Do insiders & institutionals hold more shares of PALI or FBIO?

Does the media favor PALI or FBIO?

Is PALI or FBIO more profitable?

Do analysts prefer PALI or FBIO?

Summary

How does Fortress Biotech compare to Inhibikase Therapeutics?

Do institutionals & insiders have more ownership in FBIO or IKT?

Does the media favor FBIO or IKT?

Do analysts prefer FBIO or IKT?

Is FBIO or IKT more profitable?

Which has more volatility and risk, FBIO or IKT?

Which has higher earnings and valuation, FBIO or IKT?

Summary

How does Fortress Biotech compare to Vanda Pharmaceuticals?

Which has preferable valuation and earnings, FBIO or VNDA?

Do analysts prefer FBIO or VNDA?

Which has more volatility & risk, FBIO or VNDA?

Does the media refer more to FBIO or VNDA?

Do insiders & institutionals have more ownership in FBIO or VNDA?

Is FBIO or VNDA more profitable?

Summary

How does Fortress Biotech compare to Neumora Therapeutics?

Do analysts prefer NMRA or FBIO?

Which has more risk and volatility, NMRA or FBIO?

Which has higher valuation and earnings, NMRA or FBIO?

Do insiders and institutionals believe in NMRA or FBIO?

Does the media prefer NMRA or FBIO?

Is NMRA or FBIO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBIO vs. The Competition

Fortress Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools